
FDA Warns Novo Nordisk Over PADE Reporting at US HQ
The FDA issued a Warning Letter to Novo Nordisk’s Plainsboro, New Jersey US headquarters after a January–February 2025 inspection found deficiencies in postmarketing adverse event surveillance and reporting under PADE, including issues with reporting timing and potential rejection of reports and insufficient root-cause analysis. Novo says it has a corrective action plan, has supplied seven progress updates, and remains confident it will address the regulator’s concerns. The letter follows a Form 483 and sits within broader U.S. regulatory scrutiny that includes other letters related to Ozempic/Wegovy and a Bloomington, Indiana facility, though the FDA states the warning does not judge drug quality or safety.


